Section I – Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder primarily affecting the endocrine system, which regulates blood glucose levels through hormones like insulin. This disease disrupts the body’s ability to utilise insulin effectively, leading to elevated blood sugar levels. In this essay, I will explore the pathophysiology of T2DM, including its risk factors, causes, diagnostic tests, affected physiological processes, and the primary pharmacological management using metformin. The discussion will draw on recent scholarly sources to provide a comprehensive overview.
As a student studying pathology, this topic interests me because T2DM is increasingly prevalent in the UK, affecting millions and posing significant public health challenges. My interest stems from a case I read about during my coursework: a middle-aged patient presenting with unexplained fatigue and weight loss, later diagnosed with T2DM. This real-world example highlighted the insidious nature of the disease and motivated me to delve deeper into its mechanisms, especially how lifestyle factors intersect with genetic predispositions. Understanding T2DM is crucial for future healthcare professionals, as it underscores the importance of preventive strategies in pathology.
Section II – Pathophysiology of the Disease/Process
The pathophysiology of T2DM involves a complex interplay of insulin resistance, beta-cell dysfunction, and chronic hyperglycaemia. Insulin resistance occurs when cells in muscles, fat, and the liver do not respond adequately to insulin, impairing glucose uptake (Galicia-Garcia et al., 2020). Consequently, the pancreas compensates by producing more insulin, but over time, beta-cells in the islets of Langerhans become exhausted, leading to reduced insulin secretion. This dual defect results in persistent high blood glucose levels, which can damage organs if untreated.
Risk factors for T2DM include obesity, sedentary lifestyle, age over 45, family history, and ethnicity, with South Asian and African-Caribbean populations at higher risk in the UK (NHS, 2023). Causes often stem from genetic predispositions combined with environmental cues, such as high-calorie diets and physical inactivity, which promote visceral fat accumulation and inflammation. These cues trigger inflammatory pathways, like the activation of cytokines, exacerbating insulin resistance (Ahmad et al., 2022).
Diagnostic tests are essential for confirming T2DM. The primary test is the fasting plasma glucose (FPG) level, with normal ranges below 5.6 mmol/L; a level of 7.0 mmol/L or higher indicates diabetes (WHO, 2023). Another key test is the oral glucose tolerance test (OGTT), where normal two-hour post-load glucose is under 7.8 mmol/L, but in T2DM, it exceeds 11.1 mmol/L. The glycated haemoglobin (HbA1c) test measures average blood glucose over 2-3 months, with normal levels below 42 mmol/mol (5.7%); a result of 48 mmol/mol (6.5%) or above confirms diagnosis (NHS, 2023).
In T2DM, these findings typically show elevated levels: FPG and OGTT are high due to impaired glucose regulation, and HbA1c remains elevated without intervention. With treatment, such as lifestyle changes or medication, levels can normalise; for instance, effective management often reduces HbA1c to below 53 mmol/mol (6.9%), though they may not fully return to non-diabetic ranges in advanced cases (Ahmad et al., 2022). However, if untreated, levels stay persistently high, increasing risks of complications like neuropathy.
Section III – Physiological Processes
T2DM profoundly affects several physiological processes, particularly circulation, regulation, and immunity. In terms of circulation, chronic hyperglycaemia damages vascular endothelium, leading to atherosclerosis and microvascular complications such as retinopathy and nephropathy (Galicia-Garcia et al., 2020). This impairs blood flow and oxygen delivery, heightening cardiovascular risks; indeed, T2DM patients are two to four times more likely to develop heart disease (WHO, 2023).
Regulation is disrupted at the hormonal level. The endocrine system’s insulin-glucagon balance is skewed, with glucagon overproduction contributing to hepatic glucose output. This dysregulation extends to the renin-angiotensin system, exacerbating hypertension commonly seen in T2DM (Ahmad et al., 2022). Furthermore, metabolic regulation falters, as lipid metabolism abnormalities lead to dyslipidaemia, with elevated triglycerides and low HDL cholesterol.
Immunity is also compromised; hyperglycaemia promotes oxidative stress and inflammation, weakening immune responses and increasing infection susceptibility (NHS, 2023). For example, impaired wound healing arises from reduced neutrophil function and chronic inflammation. Respiration may be indirectly affected in severe cases through conditions like sleep apnoea linked to obesity, though this is not a core feature. Overall, these disruptions create a vicious cycle, where metabolic imbalance fuels further physiological decline, highlighting T2DM’s systemic impact.
Section IV – Pharmacological Management for the Disease/Process
The primary pharmacological management for T2DM is metformin, a biguanide class drug often recommended as first-line therapy by NICE guidelines in the UK (NHS, 2023). Metformin works by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues, directly addressing the core pathophysiology of insulin resistance and hyperglycaemia.
Physiologically, metformin activates AMP-activated protein kinase (AMPK) in hepatocytes, inhibiting gluconeogenesis and reducing glucose output from the liver (Galicia-Garcia et al., 2020). It also enhances glucose uptake in skeletal muscle by improving insulin signalling pathways, such as the PI3K-Akt pathway, without stimulating insulin secretion, thus avoiding hypoglycaemia risks. Relating to pathophysiology, by countering beta-cell exhaustion, metformin helps preserve pancreatic function over time (Ahmad et al., 2022). Typically administered orally at doses of 500-2000 mg daily, its actions mitigate the inflammatory and oxidative stress associated with T2DM, potentially reducing complications like cardiovascular events.
However, metformin’s efficacy can vary; it is most effective in overweight patients and is often combined with lifestyle interventions. Side effects include gastrointestinal upset, but it remains cost-effective and widely used, with evidence from long-term studies showing reduced mortality (WHO, 2023).
Section V – Summary – Conclusion
In summary, T2DM’s pathophysiology centres on insulin resistance and beta-cell dysfunction, driven by risk factors like obesity and genetics, with diagnostic tests such as HbA1c revealing persistently elevated glucose levels that can improve with treatment. Physiological processes including circulation, hormonal regulation, and immunity are adversely affected, leading to widespread complications. Pharmacologically, metformin effectively manages the disease by enhancing insulin sensitivity and reducing hepatic glucose production, aligning closely with its underlying mechanisms.
For prevention, actions include promoting healthy diets, regular exercise, and screening high-risk groups, as emphasised by public health initiatives (NHS, 2023). Management involves multidisciplinary approaches, integrating pharmacology with education. Arguably, addressing socioeconomic factors could further reduce incidence. As a pathology student, this exploration reinforces the need for early intervention to curb T2DM’s burden, with ongoing research promising advancements in personalised treatments.
(Word count: 1,124 including references)
References
- Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022). Type 2 diabetes. The Lancet, 400(10365), 1803-1820.
- Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. International Journal of Molecular Sciences, 21(17), 6275.
- NHS. (2023). Type 2 diabetes. NHS UK.
- World Health Organization (WHO). (2023). Diabetes. WHO.
